EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Ferroptosis in heart failure: from molecular insights to therapeutic implications

Konstantinos I Karampinos, Dimitrios Farmakis iD, Rijan Gurung, Roger S Y Foo, Gerasimos S Filippatos, Dennis V Cokkinos

Cardiovascular Research · 26.03.2026 · 122 (3) · 313-335

DOI: 10.1093/cvr/cvag019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 31.01.2026. Verfasst von Konstantinos I Karampinos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, School of Medicine, Athens University Hospital Attikon, National and Kapodistrian University of Athens, Greece. Hauptthemen laut MEDLINE: Ferroptosis, Heart Failure, Lipid Peroxidation, Iron. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 118 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis is the form of regulated cell death driven by iron-induced lipid peroxidation, implicated in different cardiovascular diseases and especially heart failure. It is an abundant form of regulated cell death in the myocardium of many heart failure animal models, including the chronic ischaemic, pressure overload, diabetic, septic, obesity-related and doxorubicin-induced cardiomyopathy models. Across these models, disordered iron handling, antioxidant failure, enzymatic phospholipid peroxidation, and mitochondrial stress converge on ferroptosis, leading to contractile dysfunction and adverse remodelling. Although definitive causality between ferroptosis and heart failure has not yet been established, emerging evidence suggests that ferroptosis contributes to heart failure progression, supported by multi-layer rescue with classic inhibitors (ferrostatin-1, liproxstatin-1, iron chelators) and by cardiometabolic drugs with clinical efficacy in heart failure (sodium–glucose cotransporter 2 inhibitors, sacubitril/valsartan, finerenone, levosimendan, nicorandil) as well as polyphenols, which restore systolic and/or diastolic indices and reverse remodelling. Early human evidence aligns, showing that human failing myocardial and epicardial adipose tissue exhibit ferroptosis-specific transcriptional and lipidomic signatures, while circulating biomarkers and tissue profiles of patients receiving SGLT2 inhibitors indicate reduced ferroptosis activity. In this review, through critical synthesis of existing evidence, we analyse current literature, discuss translational barriers and propose a new conceptual mechanistic framework—‘the ferroptosis nexus’—wherein iron mobilization, antioxidant collapse, lipid priming, and mitochondrial/calcium amplifiers form a self-reinforcing loop culminating in pump failure. Standardized ferroptosis signatures, single cell and spatial transcriptomics analysis, and mechanism-driven clinical trials are needed to identify responsive heart failure phenotypes and translate ferroptosis modulation into precision cardioprotection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisHeart FailureLipid PeroxidationIronCardiovascular AgentsMitochondria, HeartMyocardiumMyocytes, CardiacHumansAnimalsVentricular RemodelingSignal TransductionIron Chelating AgentsOxidative Stress

Stichwörter der Autor:innen

FerroptosisHeart failureIronLipid peroxidationRegulated cell death

Substanzen

IronCardiovascular AgentsIron Chelating Agents

Autor:innen und Institutionen

  • Department of Cardiology, School of Medicine, Athens University Hospital Attikon, National and Kapodistrian University of Athens, Greece.
  • Cardiovascular Metabolic Disease Translational Research Program, National University Health System, Singapore.
  • Cardiovascular Research Institute, NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Clinical, Translational & Experimental Surgery Research Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

ORCID-Profile: Dimitrios Farmakis

Zitieren

APA

Karampinos, K. I., Farmakis, D., Gurung, R., Foo, R. S. Y., Filippatos, G. S., & Cokkinos, D. V. (2026). Ferroptosis in heart failure: from molecular insights to therapeutic implications. Cardiovascular Research, 122(3), 313-335. https://doi.org/10.1093/cvr/cvag019

Vancouver

Karampinos KI, Farmakis D, Gurung R, Foo RSY, Filippatos GS, Cokkinos DV. Ferroptosis in heart failure: from molecular insights to therapeutic implications. Cardiovascular Research. 2026;122(3):313-335. doi:10.1093/cvr/cvag019

BibTeX
@article{Karampinos2026,
  author = {Karampinos, Konstantinos I and Farmakis, Dimitrios and Gurung, Rijan and Foo, Roger S Y and Filippatos, Gerasimos S and Cokkinos, Dennis V},
  title = {Ferroptosis in heart failure: from molecular insights to therapeutic implications},
  journal = {Cardiovascular Research},
  year = {2026},
  volume = {122},
  number = {3},
  pages = {313--335},
  doi = {10.1093/cvr/cvag019}
}
Kostenlos starten →